U.S. IV Solutions Market to Reach $2.8 Billion by 2029, Driven by Outpatient Growth and Home-Based IV Therapy - New iData Research Report
VANCOUVER, BC, June 18, 2025 /PRNewswire/ - A new 2025 U.S. IV Solutions Market Report reveals that the IV Solutions market is projected to grow from nearly $2.1 billion in 2024 to approximately $2.8 billion by 2029, reflecting rising demand for fluid therapy across both acute and alternate care settings. The report covers U.S. market sizing, growth forecasts, pricing trends, and competitive analysis across major IV solution segments, including hydration fluids, drug reconstitution, irrigation, multi-electrolytes, and specialized formulations, used in hospitals, outpatient clinics, and home care.
Key growth drivers include rising surgical and procedural volumes, particularly in outpatient settings, increased use of IV therapy for managing chronic conditions such as cancer and renal disease, and the growing adoption of unit-dose and portable IV solutions in ambulatory care, infusion centers, and home-based treatment.
Produced by iData Research, a leading medical device market intelligence firm, the report provides critical insights for IV fluid manufacturers, procurement teams, hospital groups, infusion centers, and supply chain strategists. It outlines how providers are adapting to growing clinical complexity, shifting care delivery models, and pressure to streamline fluid therapy across settings.
"IV solutions are the foundation of modern care. As demand rises outside traditional hospital environments, manufacturers are responding with safer formulations, longer shelf lives, and packaging innovations tailored for decentralized treatment," said Dr. Kamran Zamanian, CEO of iData Research. "This market's growth reflects its expanding clinical relevance, from emergency procedures to long-term home-based care."
U.S. IV Solutions Market Expands with Shift to Outpatient and Specialized Care
While hospitals remain a major consumer of IV solutions, demand is rising fastest in ambulatory and alternate care settings, where unit-dose and portable fluid delivery formats enable efficient treatment. The ongoing integration of outpatient centers into broader health systems is also contributing to greater purchasing leverage and efficiency, though placing slight downward pressure on some ASPs.
Increased procedural volume, including surgeries, endoscopies, and diagnostic interventions, is further reinforcing demand for IV fluids, irrigation, and reconstitution solutions. IV fluids remain the market's largest segment, while drug reconstitution and irrigation solutions are the fastest-growing, driven by the rise of injectable therapies and stricter safety standards.
Meanwhile, chronic conditions such as cancer, diabetes, and renal disorders continue to drive long-term IV therapy requirements across both acute and post-acute care, adding to sustained baseline demand.
The U.S. IV Solutions Market was valued at nearly $2.1 billion following double-digit growth in 2024. This upward trend is expected to continue over the forecast period, reaching approximately $2.8 billion by 2029, fueled by rising surgical volumes, increased demand from outpatient and home-based care, and broader clinical use of IV therapy in chronic disease management.
Key Insights from the Report:
- Surgical Volume Growth: Rising procedural demand across hospitals and specialty clinics is boosting consumption of IV fluids and drug reconstitution solutions.
- Broader Clinical Applications: IV solutions now play a vital role beyond hydration, aiding in chemotherapy, contrast delivery, critical care, and surgical irrigation across inpatient and outpatient care.
- Outpatient & Infusion Center Growth: The shift toward decentralized care is accelerating demand for portable and unit-dose IV formats, especially in oncology and dialysis treatment.
- Product Innovation & ASP Stability: Despite competitive pressure, ASPs are stabilizing due to innovations such as improved fluid stability, eco-friendly packaging, and extended shelf-life solutions.
- Chronic Disease Management: The increasing prevalence of diabetes, cancer, and renal disorders is driving sustained use of IV therapy for long-term hydration, nutrition, and medication delivery.
Who Should Read This Report?
This report is designed for marketing managers, CEOs, and CFOs, along with strategic decision-makers in the cardiovascular, infusion therapy, and hospital supply sectors. It provides actionable data to benchmark competitors, identify growth segments such as drug reconstitution and outpatient IV use, and prioritize investments across care settings.
Explore the Market Report
Access a sample of the Full U.S. IV Solutions Market Report, or contact marketing for more details on market size forecasts, ASP trends, and competitive positioning.
About iData Research
iData Research has been a leader in market intelligence for the medical device industry for over 20 years, delivering data-driven insights that help companies mitigate market risks, optimize pricing strategies, and uncover new revenue opportunities.
Learn more at https://idataresearch.com/
SOURCE iData Research Inc.
Share this article